Mustang Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBIO research report →
Companywww.mustangbio.com
Mustang Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
- CEO
- Manuel Litchman
- IPO
- 2017
- Employees
- 6
- HQ
- Worcester, MA, US
Price Chart
Valuation
- Market Cap
- $4.65M
- P/E
- -1.52
- P/S
- 0.00
- P/B
- 0.48
- EV/EBITDA
- 3.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.38%
- ROIC
- -37.47%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,921,000 · 87.80%
- EPS
- $-0.39 · 84.82%
- Op Income
- $-2,432,000
- FCF YoY
- 53.87%
Performance & Tape
- 52W High
- $7.00
- 52W Low
- $0.53
- 50D MA
- $0.76
- 200D MA
- $1.16
- Beta
- 2.11
- Avg Volume
- 40.59K
Get TickerSpark's AI analysis on MBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | Litchman Manuel MD | other | 19 |
| Jan 2, 26 | Fortress Biotech, Inc. | other | 278,385 |
| Dec 30, 25 | Herskowitz Neil | sell | 247 |
| Dec 30, 25 | Chill Adam J. | sell | 4 |
| Dec 30, 25 | Jin David | buy | 247 |
| Sep 29, 25 | Fortress Biotech, Inc. | other | 59,334 |
| Apr 24, 25 | Litchman Manuel MD | other | 27 |
| Mar 31, 25 | Fortress Biotech, Inc. | other | 67,806 |
| Dec 31, 24 | Fortress Biotech, Inc. | other | 0 |
| Oct 23, 24 | Jin David | other | 0 |
Our MBIO Coverage
We haven't published any research on MBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MBIO Report →